APPLICATION VALUE OF HE4, CA125 AND ROMA IN DIAGNOSIS OF THE OVARIAN CANCER

Objective: To figure out the application values of human epididymis protein 4 (HE4), cancer antigen 125 (CA125) and risk of ovarian malignancy algorithm (ROMA) in the diagnosis of the ovarian cancer. Methods: Enzyme-linked immunosorbent assay and enhanced chemiluminescence were adopted to measure the levels of HE4 and CA125 in serum of 103 ovarian cancer patients, patients with benign tumors in ovary and 100 healthy subjects. ROMA index was calculated based on the menopause of subjects. Results: In the ovarian cancer group, levels of HE4 and CA125 in serum and ROMA index were (34532 +/- 605.02) pmol/L, (701.45 +/- 150029) U/mL and (58.71 +/- 30.99) %, respectively; in benign tumor group, these were (53.83 +/- 14.67) pmol/L, (4424 +/- 45.80) U/mL and (10.79 +/- 6.74) %, while in the healthy control group, these were (46.02 +/- 10.25) pmol/L, (17.38 +/- 10.63) U/mL and (6.91 +/- 3.84) %, respectively. Thus, the levels of HE4 and CA125 and the ROMA index in the ovarian cancer group outran those of the benign tumor group, with significant differences (P <0.05). However, differences in HE4 levels and ROMA indexes between the healthy control group and the benign tumor group were not significant (P > 0.05), and significant difference was only found in CA125 levels (P < 0.05). Besides, for diagnosis of ovarian cancer, the sensitivities of levels of HE4 and CA125 and ROMA indexes were 71.84%, 76.70% and 89.32%, and specificities were 93.43%, 53.28% and 94.89%. We also identified that any increases in the clinical stage would come with elevations in the positive rates of HE4 and ROMA index: In Stage I, the positive rates of . HE4 and ROMA index were 68% and 88%, all significandy lower than 92% of CA125. Conclusion: Combination of HE4, CA125 and ROMA index can increase the sensitivity and specificity in the diagnosis of the ovarian cancer.